We performed a narrative review with a structured literature search of MEDLINE, Embase, and ClinicalTrials.gov (January 1, 2015, to August 24, 2025) for interventional trials evaluating a PARP inhibitor combined with an anti-PD-1/PD-L1 agent in ovarian, fallopian tube, primary peritoneal, endometrial, or cervical cancer. The gene discussed is PARP1; the disease is cervical carcinoma.